JP2004528307A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004528307A5 JP2004528307A5 JP2002573009A JP2002573009A JP2004528307A5 JP 2004528307 A5 JP2004528307 A5 JP 2004528307A5 JP 2002573009 A JP2002573009 A JP 2002573009A JP 2002573009 A JP2002573009 A JP 2002573009A JP 2004528307 A5 JP2004528307 A5 JP 2004528307A5
- Authority
- JP
- Japan
- Prior art keywords
- keto
- ketoalkanoic acid
- group
- mediated
- ketoalkanoic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims 28
- 239000002253 acid Substances 0.000 claims 17
- 150000001875 compounds Chemical class 0.000 claims 10
- 230000004968 inflammatory condition Effects 0.000 claims 10
- 230000001404 mediated effect Effects 0.000 claims 8
- 102000004127 Cytokines Human genes 0.000 claims 7
- 108090000695 Cytokines Proteins 0.000 claims 7
- -1 acetoxymethyl Chemical group 0.000 claims 5
- 150000002148 esters Chemical class 0.000 claims 5
- 239000011575 calcium Substances 0.000 claims 4
- 239000012876 carrier material Substances 0.000 claims 4
- 150000001768 cations Chemical class 0.000 claims 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 3
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 150000001408 amides Chemical class 0.000 claims 3
- 229910052791 calcium Inorganic materials 0.000 claims 3
- 239000011777 magnesium Substances 0.000 claims 3
- XXRCUYVCPSWGCC-UHFFFAOYSA-N Ethyl pyruvate Chemical compound CCOC(=O)C(C)=O XXRCUYVCPSWGCC-UHFFFAOYSA-N 0.000 claims 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 125000004181 carboxyalkyl group Chemical group 0.000 claims 2
- RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 claims 2
- 238000005837 enolization reaction Methods 0.000 claims 2
- 229940117360 ethyl pyruvate Drugs 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 229910052749 magnesium Inorganic materials 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 230000000087 stabilizing effect Effects 0.000 claims 2
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 claims 1
- TYEYBOSBBBHJIV-UHFFFAOYSA-N 2-oxobutanoic acid Chemical compound CCC(=O)C(O)=O TYEYBOSBBBHJIV-UHFFFAOYSA-N 0.000 claims 1
- XNIHZNNZJHYHLC-UHFFFAOYSA-N 2-oxohexanoic acid Chemical compound CCCCC(=O)C(O)=O XNIHZNNZJHYHLC-UHFFFAOYSA-N 0.000 claims 1
- KDVFRMMRZOCFLS-UHFFFAOYSA-N 2-oxopentanoic acid Chemical compound CCCC(=O)C(O)=O KDVFRMMRZOCFLS-UHFFFAOYSA-N 0.000 claims 1
- QHKABHOOEWYVLI-UHFFFAOYSA-N 3-methyl-2-oxobutanoic acid Chemical compound CC(C)C(=O)C(O)=O QHKABHOOEWYVLI-UHFFFAOYSA-N 0.000 claims 1
- BKAJNAXTPSGJCU-UHFFFAOYSA-N 4-methyl-2-oxopentanoic acid Chemical compound CC(C)CC(=O)C(O)=O BKAJNAXTPSGJCU-UHFFFAOYSA-N 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 102000003777 Interleukin-1 beta Human genes 0.000 claims 1
- 108090000193 Interleukin-1 beta Proteins 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 239000012891 Ringer solution Substances 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims 1
- 229940120503 dihydroxyacetone Drugs 0.000 claims 1
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 claims 1
- FJAKCEHATXBFJT-UHFFFAOYSA-N ethyl 2-oxobutanoate Chemical compound CCOC(=O)C(=O)CC FJAKCEHATXBFJT-UHFFFAOYSA-N 0.000 claims 1
- WRQGPGZATPOHHX-UHFFFAOYSA-N ethyl 2-oxohexanoate Chemical compound CCCCC(=O)C(=O)OCC WRQGPGZATPOHHX-UHFFFAOYSA-N 0.000 claims 1
- YERWBBMSDMSDKT-UHFFFAOYSA-N ethyl 2-oxopentanoate Chemical compound CCCC(=O)C(=O)OCC YERWBBMSDMSDKT-UHFFFAOYSA-N 0.000 claims 1
- CKTYYUQUWFEUCO-UHFFFAOYSA-N ethyl 3-methyl-2-oxobutanoate Chemical compound CCOC(=O)C(=O)C(C)C CKTYYUQUWFEUCO-UHFFFAOYSA-N 0.000 claims 1
- MGSWAHQQBHNCEI-UHFFFAOYSA-N ethyl 4-methyl-2-oxopentanoate Chemical compound CCOC(=O)C(=O)CC(C)C MGSWAHQQBHNCEI-UHFFFAOYSA-N 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 229910001414 potassium ion Inorganic materials 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- FPOLWERNILTNDK-UHFFFAOYSA-N pyruvamide Chemical compound CC(=O)C(N)=O FPOLWERNILTNDK-UHFFFAOYSA-N 0.000 claims 1
- 229940107700 pyruvic acid Drugs 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 239000012266 salt solution Substances 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 102000003390 tumor necrosis factor Human genes 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27627901P | 2001-03-15 | 2001-03-15 | |
| PCT/US2002/008283 WO2002074301A1 (en) | 2001-03-15 | 2002-03-15 | Method of using pyruvate and/or its derivatives for the treatment of cytokine-mediated inflammatory conditions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004528307A JP2004528307A (ja) | 2004-09-16 |
| JP2004528307A5 true JP2004528307A5 (https=) | 2005-12-22 |
Family
ID=23055992
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002573009A Pending JP2004528307A (ja) | 2001-03-15 | 2002-03-15 | サイトカインにより媒介される炎症性状態の治療のためのピルベートおよび／またはその誘導体の使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US6943190B2 (https=) |
| EP (1) | EP1379230A4 (https=) |
| JP (1) | JP2004528307A (https=) |
| AU (1) | AU2002255805B2 (https=) |
| CA (1) | CA2440480A1 (https=) |
| WO (1) | WO2002074301A1 (https=) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6303321B1 (en) | 1999-02-11 | 2001-10-16 | North Shore-Long Island Jewish Research Institute | Methods for diagnosing sepsis |
| WO2002074301A1 (en) * | 2001-03-15 | 2002-09-26 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Method of using pyruvate and/or its derivatives for the treatment of cytokine-mediated inflammatory conditions |
| EP1377339A4 (en) * | 2001-04-04 | 2006-05-31 | Critical Therapeutics Inc | PROCEDURE FOR PREVENTING AKUTER NIERENINSUFFIZIENZ |
| DE60228954D1 (en) | 2001-05-03 | 2008-10-30 | Galileo Lab Inc | Pyruvatderivate |
| US7304034B2 (en) | 2001-05-15 | 2007-12-04 | The Feinstein Institute For Medical Research | Use of HMGB fragments as anti-inflammatory agents |
| US8076373B2 (en) * | 2001-09-11 | 2011-12-13 | North Cell Pharmacetical | Method for treating mammalian diseases and injuries caused by the over-expression of peroxynitrite |
| US7122578B2 (en) * | 2001-09-11 | 2006-10-17 | Alain Martin | Method and composition for treating mammalian diseases and injuries which cause pain, erythema, swelling, crusting, ischemia scarring and excess white blood cell infiltration |
| AU2003228099A1 (en) * | 2002-07-03 | 2004-01-23 | Centro Cardiologico Monzino S.P.A.-Irccs | Use of hmgb1 in the treatment of tissue damage and/or to promote tissue repair |
| WO2004052365A2 (en) * | 2002-12-06 | 2004-06-24 | North Shore-Long Island Jewish Research Institute | Inhibition of inflamation using alpha 7 receptor-binding cholinergic agonists |
| US7696169B2 (en) | 2003-06-06 | 2010-04-13 | The Feinstein Institute For Medical Research | Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents |
| CA2528144A1 (en) * | 2003-06-09 | 2005-01-20 | Mitchell P. Fink | Method for treating acute pancreatitis |
| WO2005002563A2 (en) * | 2003-06-13 | 2005-01-13 | University Of Pittsburgh - Of The Commonwealth System Of Higher Eduction | Method for treating alcoholic hepatitis |
| ES2222093A1 (es) | 2003-07-01 | 2005-01-16 | Advanced In Vitro Cell Technologies, S.L. | Metodo para el almacenamiento y/o transporte de cultivos celulares in vitro. |
| CA2882022A1 (en) | 2003-09-11 | 2005-03-24 | Walter Newman | Monoclonal antibodies against hmgb1 |
| US20050095246A1 (en) * | 2003-10-24 | 2005-05-05 | Medtronic, Inc. | Techniques to treat neurological disorders by attenuating the production of pro-inflammatory mediators |
| WO2006012373A2 (en) * | 2004-07-20 | 2006-02-02 | Critical Therapeutics, Inc. | Combination therapies of hmgb and complement inhibitors against inflammation |
| US20060253100A1 (en) | 2004-10-22 | 2006-11-09 | Medtronic, Inc. | Systems and Methods to Treat Pain Locally |
| EP1874407B1 (en) | 2005-04-15 | 2015-09-09 | Biomac Privatinstitut für medizinische und Zahnmedizinische Forschung, Entwicklung und Diagnostik GmbH | Substances and pharmaceutical compositions for the inhibition of glyoxalases and their use as anti-fungal agents |
| WO2007011606A2 (en) * | 2005-07-18 | 2007-01-25 | Critical Therapeutics, Inc. | USE OF HMGBl ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY SKIN CONDITIONS |
| JP2009533433A (ja) * | 2006-04-12 | 2009-09-17 | アレクサンダー，ランヤ，エル． | ピルビン酸アルキルエステルを含む組成物とその使用 |
| US7754247B2 (en) * | 2007-05-29 | 2010-07-13 | University Of South Carolina | Resuscitation fluid |
| US8211943B2 (en) * | 2007-08-08 | 2012-07-03 | Alain Martin | Method for treating a pulmonary disease state in mammals by up regulating indigenous in vivo levels of inflammatory agents in mammalian cells |
| US8114907B2 (en) * | 2007-08-08 | 2012-02-14 | Cellular Sciences Inc | Method for treating a pulmonary disease state in mammals by up regulating indigenous in vivo levels of inflammatory agents in mammalian cells |
| US8815946B2 (en) * | 2008-01-25 | 2014-08-26 | University of Pittsburgh—of the Commonwealth System of Higher Education | Inhibition of proliferation and fibrotic response of activated corneal stromal cells |
| JP5630750B2 (ja) * | 2008-03-18 | 2014-11-26 | 国立大学法人 岡山大学 | 興奮性化学伝達調節剤およびそのスクリーニング法 |
| USRE48948E1 (en) | 2008-04-18 | 2022-03-01 | Warsaw Orthopedic, Inc. | Clonidine compounds in a biodegradable polymer |
| MX2011005207A (es) | 2008-11-20 | 2011-07-20 | Chata Biosystems Inc | Alfa-ceto peracidos y metodos para producir y utilizar los mismos. |
| US8445717B2 (en) | 2008-11-20 | 2013-05-21 | Chd Bioscience, Inc. | α-Keto alkylperacids and methods for producing and using the same |
| CA2750140C (en) | 2008-12-30 | 2015-10-06 | Hill's Pet Nutrition, Inc. | Use of lipoic acid for treating or preventing degenerative joint conditions, osteoarthritis, cartilage damage, and related disorders in companion animals |
| US20100239632A1 (en) | 2009-03-23 | 2010-09-23 | Warsaw Orthopedic, Inc. | Drug depots for treatment of pain and inflammation in sinus and nasal cavities or cardiac tissue |
| AU2010343129B2 (en) * | 2009-12-29 | 2013-05-16 | Hill's Pet Nutrition, Inc. | Compositions including pyruvate for companion animals and methods of use thereof |
| US11284621B2 (en) | 2010-04-15 | 2022-03-29 | Armis Biopharma, Inc. | Compositions comprising peroxyacid and methods for producing and using the same |
| JP6291256B2 (ja) * | 2011-02-17 | 2018-03-14 | シーエイチディー・バイオサイエンス，インコーポレーテッド | ペルオキシα−ケトカルボン酸を含む組成物、および該組成物を産生し、そして用いるための方法 |
| US9044527B2 (en) | 2011-02-17 | 2015-06-02 | Chd Bioscience, Inc. | Wound care products with peracid compositions |
| US9913880B2 (en) * | 2011-02-18 | 2018-03-13 | Stemdr Inc. | Method of treating sepsis or septic shock |
| WO2012170742A2 (en) | 2011-06-07 | 2012-12-13 | University Of Hawaii | Treatment and prevention of cancer with hmgb1 antagonists |
| US9244074B2 (en) * | 2011-06-07 | 2016-01-26 | University Of Hawaii | Biomarker of asbestos exposure and mesothelioma |
| EP2908810A2 (en) | 2012-10-18 | 2015-08-26 | CHD Bioscience, Inc. | Stable peracid-containing compositions |
| US9578879B1 (en) | 2014-02-07 | 2017-02-28 | Gojo Industries, Inc. | Compositions and methods having improved efficacy against spores and other organisms |
| DE102017131059A1 (de) * | 2017-12-22 | 2019-06-27 | Christiane Kappert | Physiologisch verträgliche Lösung mit einem Gehalt an Pyruvat und Glycin, eine Pyruvat und Glycin enthaltende Zusammensetzung und Verfahren zu deren Herstellung |
| EP3797766A1 (en) * | 2019-09-24 | 2021-03-31 | Evonik Operations GmbH | Compositions for use in reducing inflammation |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2307075A (en) * | 1940-08-02 | 1943-01-05 | Carbide And Carbon Chemicais C | Vinyl resin composition |
| US4105782A (en) * | 1975-03-07 | 1978-08-08 | Yu Ruey J | Treatment of acne and dandruff |
| US4197316A (en) * | 1975-07-23 | 1980-04-08 | Scott Eugene J Van | Treatment of dry skin |
| JPS539847A (en) * | 1976-07-15 | 1978-01-28 | Akishima Kagaku Kogyo | Stabilized halogenncontained resin composition |
| US4234599A (en) * | 1978-10-04 | 1980-11-18 | Scott Eugene J Van | Treatment of skin keratoses with α-hydroxy acids and related compounds |
| US4246261A (en) * | 1979-08-09 | 1981-01-20 | Scott Eugene J Van | Additives enhancing topical corticosteroid action |
| DE3133132A1 (de) * | 1981-08-21 | 1983-03-03 | Schweiger Hubert | Terpene in synergistisch wirkenden kombinationen mit (alpha)-ketomono- und/oder (alpha)-ketodicarbonsaeuren und/oder deren mono- bzw. mono- und/oder diester und verwendung dieser pflanzlichen wirkstoffkombinationen als bioaktive mittel in arznei-, kosmetischen und dermatologischen mitteln |
| EP0215138B1 (fr) | 1985-09-06 | 1991-01-16 | Societe Des Produits Nestle S.A. | Préservation des tissus vivants |
| US6051609A (en) | 1997-09-09 | 2000-04-18 | Tristrata Technology, Inc. | Additives enhancing the effect of therapeutic agents |
| US5210098A (en) | 1990-09-21 | 1993-05-11 | Regents Of The University Of Minnesota | Use of pyruvate to treat acute renal failure |
| AU8539491A (en) * | 1990-09-21 | 1992-04-15 | Regents Of The University Of Minnesota | Pyruvate solutions to counteract acute renal failure |
| US5648380A (en) | 1991-03-01 | 1997-07-15 | Warner-Lambert Company | Anti-inflammatory wound healing compositions and methods for preparing and using same |
| WO1993006726A1 (en) | 1991-09-30 | 1993-04-15 | Mackenzie Walser | Methods for treatment of free-radical-mediated tissue injury |
| DE4415581C2 (de) * | 1994-05-04 | 1995-12-07 | Voith Gmbh J M | Papier-Streichvorrichtung |
| US5536751A (en) * | 1994-05-09 | 1996-07-16 | The United States Of America As Represented By The Secretary Of The Army | Pharmaceutical alpha-keto carboxylic acid compositions method of making and use thereof |
| US5480909A (en) | 1994-08-08 | 1996-01-02 | University Of Pittsburgh Medical Center | Method for inhibiting generation of free-radicals |
| US5908611A (en) | 1995-05-05 | 1999-06-01 | The Scripps Research Institute | Treatment of viscous mucous-associated diseases |
| AU719332B2 (en) * | 1995-09-19 | 2000-05-04 | Cellular Sciences, Inc. | Method and composition for treating mammalian diseases caused by inflammatory response |
| US5798388A (en) * | 1996-09-06 | 1998-08-25 | Cellular Sciences, Inc. | Method and composition for treating mammalian diseases caused by inflammatory response |
| US6086789A (en) | 1996-03-18 | 2000-07-11 | Case Western Reserve University | Medical uses of pyruvates |
| US5756469A (en) | 1996-07-26 | 1998-05-26 | Beale; Paxton K. | Composition of pyruvate and anti-cortisol compounds and method for increasing protein concentration in a mammal |
| US6417231B1 (en) * | 1996-12-23 | 2002-07-09 | Frank L. Greenway | Method and composition for delivering therapeutically effective amounts of pyruvate to a mammal |
| JP4885362B2 (ja) | 1999-05-14 | 2012-02-29 | セルラー サイエンセズ インコーポレイテッド | 炎症反応により生ずる哺乳動物の鼻および副鼻洞の病気を処置する方法および組成物 |
| CN1377266A (zh) * | 1999-10-07 | 2002-10-30 | 安瑟斯生命科学公司 | 丙酮酸酯组合物和其在缺血和灌流后复苏中的应用方法 |
| US6846842B2 (en) * | 1999-10-07 | 2005-01-25 | Beth Israel Deconess Medical Center, Inc. | Pyruvate ester composition and method of use for resuscitation after events of ischemia and reperfusion |
| WO2002074301A1 (en) * | 2001-03-15 | 2002-09-26 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Method of using pyruvate and/or its derivatives for the treatment of cytokine-mediated inflammatory conditions |
-
2002
- 2002-03-15 WO PCT/US2002/008283 patent/WO2002074301A1/en not_active Ceased
- 2002-03-15 JP JP2002573009A patent/JP2004528307A/ja active Pending
- 2002-03-15 AU AU2002255805A patent/AU2002255805B2/en not_active Ceased
- 2002-03-15 CA CA002440480A patent/CA2440480A1/en not_active Abandoned
- 2002-03-15 EP EP02725226A patent/EP1379230A4/en not_active Withdrawn
-
2003
- 2003-09-15 US US10/662,975 patent/US6943190B2/en not_active Expired - Fee Related
-
2005
- 2005-03-31 US US11/095,031 patent/US20050245609A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004528307A5 (https=) | ||
| JP2004501189A5 (https=) | ||
| CN1088992C (zh) | 治疗眼炎的含3－苯甲酰基苯乙酸衍生物的局部给药组合物 | |
| RU2003135482A (ru) | Геропротектор на основе гидрированных пиридо(4,3-b) индолов (варианты), фармакологическое средство на его основе и способ его применения | |
| RU2008106058A (ru) | Производные пиридазинона в качестве агонистов рецептора тиреоидного гормона | |
| JP2011510080A5 (https=) | ||
| JP2004516314A5 (https=) | ||
| JP2004512318A (ja) | Ｃ−ニトロソ化合物とその使用 | |
| RU2003103286A (ru) | Ингибиторы медьсодержащих аминооксидаз | |
| RU2008109914A (ru) | Применение производных тиенопиридона в качестве активаторов амфк и фармацевтические композиции, которые их содержат | |
| JP2009530398A5 (https=) | ||
| JP2011507896A5 (https=) | ||
| RU2005128501A (ru) | Соединение для лечения метаболических расстройств | |
| RU2000116899A (ru) | Тиенопиримидины | |
| JP2005527592A5 (https=) | ||
| CA2522738A1 (en) | Compounds for the treatment of metabolic disorders | |
| CA2521621A1 (en) | Compounds for the treatment of metabolic disorders | |
| EP1494659B1 (en) | Pharmaceutical composition comprising an alpha-ketoalkanoic acid ester or -amide and lactic acid or a lactic acid salt | |
| AU2014203872A1 (en) | Use of fatty acid niacin conjugates for treating diseases | |
| JP2004502732A5 (https=) | ||
| JP2007501800A5 (https=) | ||
| JP2005527479A5 (https=) | ||
| RU2000129659A (ru) | Конденсированные тиенопиримидины с ингибирующим фосфодиэстеразу v действием | |
| RU96123227A (ru) | Амидные производные и их терапевтическое использование | |
| RU2013126522A (ru) | Лизурид, тергурид и их производные для применения в профилактике и/или лечении фиброзных изменений |